Health TechRead more
BII aims to support women’s health across a broad range of indication areas. We are especially interested in new non-hormonal therapeutics solutions, and evidence-based health tech approaches. For specifics, please click on the images below.
BII offers several ways to apply for funding for your women’s health start-up or project. Currently, we have a special funding opportunity with Ferring Pharmaceuticals A/S through a Reproductive Medicine and Maternal Health track. Learn more by clicking the boxes below.
The panel assesses applications for BII’s programs and supports the continuous development of BII’s strategy within women’s health. Members of the panel are leading academics, VCs, entrepreneurial experts, and key industry representatives – a broad representation of the innovation pipeline within women’s health.
Below you can read all the news related to BII’s Women’s Health Initiative.
BII’s Women’s Health Initiative aims to strengthen the European ecosystem for innovative translational research and start-ups that address the high medical unmet needs within women’s health.
Parts of the Women’s Health Initiative activities are supported by a grant from Bill & Melinda Gates Foundation.
As part of this joint initiative, BII will conduct a thorough landscape analysis and identify leading research and start-up opportunities for women’s health, with the potential for future funding from BII and partners.
BII will also undertake community-building and awareness-creating activities with selected key partners within the ecosystem.
Develops a molecular point-of-care test for fast and accurate diagnosis of sexually transmitted infections.
Targeted immunotherapy for efficient and safe treatment of patients with HPV, dysplasia, and cancer.
Developing a drug discovery platform using human embryo models for women’s reproductive health.
Developing the first disease-modifying treatment for endometriosis.
Precision oncology start-up developing targeted treatments for breast cancer brain metastatic patients.
Developing a first-in-class treatment for infertile women who do not benefit from standard hormone therapy.
Developing a novel first-in-class treatment for male infertility.
A novel approach to birth control, aiming to reinforce the natural cervical mucus barrier without hormones.
At BioInnovation Institute (BII), we accelerate world-class life science start-up innovation to benefit people and society. As a non-profit institute, BII operates the company creation programs, Bio Studio, Venture Lab and Venture House, to support life science start-ups with knowledge, network, infrastructure and funding of up to 3M EUR per project and 1,8 M EUR per start-up. With our expertise, network, funding, and infrastructure, we empower startups to succeed and believe in the transformative power of life science innovation
Since the inauguration of BII in November 2018, BII has awarded 83 million euros to 88 high-growth start-up companies and translational projects.